Researchers demonstrated a bnew blood test, CORE (Cirrhosis Outcome Risk Estimator) method for severe liver disease prognosis. This simple blood...
Vous n'êtes pas connecté
Menlo Park─based MyOme, a clinical whole genome analysis company helping families understand their risk for diseases, has announced the expansion of its rare disease test to include tandem repeat expansions
Researchers demonstrated a bnew blood test, CORE (Cirrhosis Outcome Risk Estimator) method for severe liver disease prognosis. This simple blood...
Competitive: Worldwide Clinical Trials - USA: Who we are We're a global, midsize CRO that pushes boundaries, innovates and invents because the path...
Competitive: Worldwide Clinical Trials - USA: Who we are We're a global, midsize CRO that pushes boundaries, innovates and invents because the path...
Competitive: ICON Plc: Clinical Trial Manager - CNS/Rare Diseases ICON plc is a world-leading healthcare intelligence and clinical research...
Whole genome sequencing offered to breast cancer patients is likely to identify unique genetic features that could either guide immediate treatment or...
Huntington's disease is an inherited genetic disease, causing progressive damage to certain nerve cells in the brain. This damage worsens over time...
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to...
Company Expands Service Footprint Across U.S. and Canada, Enters New States, and Strengthens Employee Transportation Offerings ......
Company Expands Service Footprint Across U.S. and Canada, Enters New States, and Strengthens Employee Transportation Offerings ......
Company Expands Service Footprint Across U.S. and Canada, Enters New States, and Strengthens Employee Transportation Offerings ......